Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas C Turner

Showing results (71-80 of 138) with videos related to

Pageof 14
Sort By:
Nature Communications|January 23, 2015
Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumoursKevin Litchfield, Brenda Summersgill, Shawn Yost, et al.
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast CancerUzma S Asghar, Alexis R Barr, Ros Cutts, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Breast Cancer Research and Treatment|August 13, 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trialsRichard S Finn, Massimo Cristofanilli, Johannes Ettl, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast CancerKomal L Jhaveri, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2019
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast CancerNicholas C Turner, Yuan Liu, Zhou Zhu, et al.
The Oncologist|May 6, 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal MetastasisAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studiesHope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Pageof 14

Showing results (71-80 of 138) with videos related to

Sort By:
Pageof 14
Nature Communications|January 23, 2015
Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumoursKevin Litchfield, Brenda Summersgill, Shawn Yost, et al.
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast CancerUzma S Asghar, Alexis R Barr, Ros Cutts, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Breast Cancer Research and Treatment|August 13, 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trialsRichard S Finn, Massimo Cristofanilli, Johannes Ettl, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast CancerKomal L Jhaveri, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2019
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast CancerNicholas C Turner, Yuan Liu, Zhou Zhu, et al.
The Oncologist|May 6, 2021
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3Hiroji Iwata, Yoshiko Umeyama, Yuan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal MetastasisAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studiesHope S Rugo, Nicholas C Turner, Richard S Finn, et al.
Pageof 14